hgen_home_2.png

The Cytokine Storm Company

Humanigen, Inc.

Recent News

July 9, 2021
UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

May 28, 2021
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.

AdobeStock_203971424.jpeg

"The more original a discovery the more obvious it seems afterwards."

Arthur Koestler